Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate
Phase 1/2ActiveDevelopment Stage
Aggressive Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Nov 20, 2018 → Jun 11, 2025
About Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate
Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate is a phase 1/2 stage product being developed by Bristol Myers Squibb for Aggressive Non-Hodgkin Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03704714. Target conditions include Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03704714 | Phase 1/2 | Active |
Competing Products
11 competing products in Aggressive Non-Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy | Johnson & Johnson | Phase 2 | 52 |
| Loncastuximab Tesirine and Epcoritamab | AbbVie | Phase 2 | 52 |
| Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib | AstraZeneca | Phase 2 | 52 |
| Midostaurin | Novartis | Phase 2 | 52 |
| Imatinib | Novartis | Phase 2 | 52 |
| Bendamustine and subcutaneous rituximab | Roche | Phase 2 | 52 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 2 | 51 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| cemiplimab + odronextamab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| PRT2527 + Zanubrutinib + Venetoclax | Prelude Therapeutics | Phase 1 | 25 |